Metabolic signature identifies novel targets for drug resistance in multiple myeloma. - Wikidata - awgldk - TriplyDB

Metabolic signature identifies novel targets for drug resistance in multiple myeloma.

Metabolic signature identifies novel targets for drug resistance in multiple myeloma.

http://www.wikidata.org/entity/Q35612105

about

Hypoxia-inducible microRNA-210 regulates the DIMT1-IRF4 oncogenic axis in multiple myeloma Pharmacogenomics and chemical library screens reveal a novel SCFSKP2 inhibitor that overcomes Bortezomib resistance in multiple myeloma.Homoharringtonine delivered by high proportion PEG of long- circulating liposomes inhibits RPMI8226 multiple myeloma cells in vitro and in vivo Navigating the bone marrow niche: translational insights and cancer-driven dysfunction.Effects of survivin on FVADT chemotherapy for refractory multiple myeloma.Potential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma.Proteomic identification of the lactate dehydrogenase A in a radioresistant prostate cancer xenograft mouse model for improving radiotherapy.Stable shRNA Silencing of Lactate Dehydrogenase A (LDHA) in Human MDA-MB-231 Breast Cancer Cells Fails to Alter Lactic Acid Production, Glycolytic Activity, ATP or Survival.Extracellular matrix protein Reelin promotes myeloma progression by facilitating tumor cell proliferation and glycolysis.Targeting of cell metabolism in human acute myeloid leukemia--more than targeting of isocitrate dehydrogenase mutations and PI3K/AKT/mTOR signaling?Microvesicles derived from normal and multiple myeloma bone marrow mesenchymal stem cells differentially modulate myeloma cells' phenotype and translation initiation.PEGylated long-circulating liposomes deliver homoharringtonine to suppress multiple myeloma cancer stem cells Cell intrinsic and extrinsic regulation of leukemia cell metabolism.A DNA-binding Molecule Targeting the Adaptive Hypoxic Response in Multiple Myeloma Has Potent Antitumor Activity.Efficacy of the HSP70 inhibitor PET-16 in multiple myeloma.KLF4-SQSTM1/p62-associated prosurvival autophagy contributes to carfilzomib resistance in multiple myeloma models.The hypoxia signalling pathway in haematological malignancies.Drug resistance in hematologic malignancies: induction mechanisms, genetics, and therapeutics.Bortezomib resistance in multiple myeloma is associated with increased serine synthesis.Exosomal miRNAs and miRNA dysregulation in cancer-associated fibroblasts.Restoration of the prolyl-hydroxylase domain protein-3 oxygen-sensing mechanism is responsible for regulation of HIF2α expression and induction of sensitivity of myeloma cells to hypoxia-mediated apoptosis.De novo MYC addiction as an adaptive response of cancer cells to CDK4/6 inhibition.Evolutionary biology of high-risk multiple myeloma.Tris DBA palladium overcomes hypoxia-mediated drug resistance in multiple myeloma.Hypoxia favors the generation of human plasma cells.Perturbation-response genes reveal signaling footprints in cancer gene expression.Targeted knockdown of DJ-1 induces multiple myeloma cell death via KLF6 upregulation.The bone-marrow niche in MDS and MGUS: implications for AML and MM.CD69 is a direct HIF-1α target gene in hypoxia as a mechanism enhancing expression on tumor-infiltrating T lymphocytes.Metabolic Features of Multiple Myeloma.Elevated lactate dehydrogenase (LDH) can be a marker of immune suppression in cancer: Interplay between hematologic and solid neoplastic clones and their microenvironments.The role of HIF-1α in chemo-/radioresistant tumors.A set of cancer stem cell homing peptides associating with the glycan moieties of glycosphingolipids.Pterostilbene inhibits nutrient metabolism and induces apoptosis through AMPK activation in multiple myeloma cells PGC1β regulates multiple myeloma tumor growth through LDHA-mediated glycolytic metabolism The metabolomic plasma profile of myeloma patients is considerably different from healthy subjects and reveals potential new therapeutic targets The Influence of Metabolism on Drug Response in Cancer

P2860

Q33607455-3C079470-7286-408A-85BD-93D4759163B6 Q36146344-3DCDBC5C-A652-4E0D-8F00-73DED69B557B Q36878540-2BED836A-44C5-4EB6-A6A7-FB527CCFFFF1 Q37101382-5F621D44-8336-4BA1-85D1-93050946358C Q37108574-25CA3FB9-5F33-4E02-B215-60D54877889D Q37327618-8F4C0E9C-DC31-4922-9F2A-506410AA5744 Q37687556-65BE79EF-E44F-485D-B766-593BAC8A915E Q37718064-E5288DED-5848-4A4A-AEFE-11030E104AFA Q37721603-B80F3CC2-64E8-44D0-80B9-266E883FE365 Q38606849-7694CB5D-B454-4EF1-B1BF-897782F1F6B9 Q38609866-DE81F8FB-0DE4-42D6-A547-65CE0D00ED53 Q38722800-C6AF9C68-5115-4BF7-8C25-1530912456E8 Q38742000-68312CFB-ABBD-4E17-A060-C0128F3A33F6 Q38800369-52DBD944-FA0A-410C-979A-1E1A83236201 Q38852874-C8EBA2AF-81F3-4620-A8D7-F9C47529AADC Q38860336-C2CFCD03-BA5F-440F-B132-36B89B91142A Q39246376-470F0510-8638-455A-B44A-C4F06DDD9093 Q40526451-F9B3DD66-2FC3-4D47-9373-8B59C34FEE11 Q41554672-EE1F7929-5F2E-4241-B180-BFCB421D71FF Q41557851-143829EE-4E14-44B9-902F-0C3891BE1BDD Q46448023-45C6FD1D-049C-40D7-9310-C16DBC83215C Q47095669-0C2DE2CE-CB7F-4483-ABE7-7388420CA8BF Q47913337-93B51E21-778B-45AE-9C92-48EDBD461B34 Q48073647-A81B6BB8-2444-4D91-AB41-5B6040616F2B Q48207902-1EC7AC71-B121-4EB8-9CC6-FD466503C86E Q48319034-E3BBF8AD-B2AA-40B8-AB6F-00242286131B Q48955308-A061513F-AE6A-439F-9A6A-8B541AC5DA7D Q50114615-60F3BE38-9FDF-4D34-8352-9332FAFA44D8 Q50424224-14FEA467-585F-4B8C-B512-FD50342C1250 Q53694850-B22A3D2D-E32F-4CC8-8F4B-6DBB4224E9AB Q53737755-E5278744-0601-4F32-9C13-0C5FF8C292FB Q55005742-F004EE6F-7C67-452F-BB38-AF5BC1FC744D Q55399318-D0A8B6D8-4249-43FA-83D9-353E24DD782E Q58762272-51C6BFB9-46CF-407B-A5CC-0CF7F9204E6C Q58780167-E876ABF8-4534-4C66-A691-5B68C5D50A1A Q58791203-9DA4F69B-8EFD-4319-AB30-A367ABBA5926 Q59136910-D29BCD5A-C376-48F1-9791-AB3EE2CB6515

P2860

Metabolic signature identifies novel targets for drug resistance in multiple myeloma.

http://www.wikidata.org/entity/Q35612105

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Metabolic signature identifies novel targets for drug resistance in multiple myeloma.

@ast

Metabolic signature identifies novel targets for drug resistance in multiple myeloma.

@en

type

label

Metabolic signature identifies novel targets for drug resistance in multiple myeloma.

@ast

Metabolic signature identifies novel targets for drug resistance in multiple myeloma.

@en

prefLabel

Metabolic signature identifies novel targets for drug resistance in multiple myeloma.

@ast

Metabolic signature identifies novel targets for drug resistance in multiple myeloma.

@en

P1433

Q35612105-8CC77391-5EDD-4B08-8C92-097C325843A2

P1476

Q35612105-025F06E5-4BF1-4B08-A2EC-576033E2C240

P2093

Q35612105-178FF86B-0A7D-40A0-AB04-D75788FEB7BA

Q35612105-2C3E1328-BA41-4D44-8B50-EAD29BC3F756

Q35612105-8077CB24-074F-4BE3-B10A-159579F8E6EC

Q35612105-9C4973D7-33B1-41C5-8B97-A092497DCF87

Q35612105-BD2C5E18-B847-4C40-978C-CED5EB74C6A2

Q35612105-C05E1E65-1C77-4D37-9E9F-71B741521AEF

Q35612105-F9CC4072-3336-49E5-A1B0-27517D75E1B4

P2860

Q35612105-1F6AA808-E2DA-4BA3-91D7-A54DF20DCAA7

Q35612105-1F9F518F-BDC4-4F0F-930B-39A612D2373C

Q35612105-23E9B484-00D7-454B-AAC6-F0F5219B2458

Q35612105-312287FA-1450-4B21-94A6-E58D74283C29

Q35612105-33297E0C-E6C3-401B-99FB-EFD2FB49348B

Q35612105-3A2C6D77-5AF9-4464-8A88-F01115BF725B

Q35612105-3B093F93-D15F-4C78-BD6E-2D1BC0D080E8

Q35612105-3B8B5029-6CA7-441F-9ECE-20929E45FC72

Q35612105-3BE11AB7-1A2E-47B9-841B-AAB50CD7FF94

Q35612105-3C9EF7F5-8C6F-4463-A38D-9CCFC84EA041

P304

Q35612105-3CA235BF-661A-4091-9C97-F5297B4D32EF

P31

Q35612105-BE86D35B-E56A-48D8-AAF4-C8DF81A1E70D

P356

Q35612105-EFD55563-C880-40AF-912C-4322416BED85

P407

Q35612105-6425220F-5FD0-41FC-9078-BAA8BBCB8669

P433

Q35612105-5EF34C46-649D-4AD7-B325-5D2DE8506030

P478

Q35612105-B1145845-B49A-47F4-89F8-722986FAE983

P50

Q35612105-9FF5D72D-D605-41AD-9D3A-53E95F596A29

Q35612105-D5DEE51F-DA81-4A48-A6FC-0EFFE4943291

Q35612105-F9B0C20E-6734-454E-B3A9-77E449E2EDBE

P577

Q35612105-F9383A73-FF38-4EE7-B7CC-FC33E154DDF1

P698

Q35612105-DA040E22-7B03-44BE-8468-0AC8F7DC2630

P921

Q35612105-01397DB2-39B6-40F2-B769-03073B36FC7F

P932

Q35612105-900A94D0-80EF-42CC-9784-7967551E6709

P356

0008-5472.CAN-14-3400

P1433

Cancer Research

P1476

Metabolic signature identifies novel targets for drug resistance in multiple myeloma.

@en

P2093

Alec C Kimmelman

http://www.w3.org/2001/XMLSchema#string

Daisy Huynh

http://www.w3.org/2001/XMLSchema#string

Irene M Ghobrial

http://www.w3.org/2001/XMLSchema#string

John M Asara

http://www.w3.org/2001/XMLSchema#string

Michele Moschetta

http://www.w3.org/2001/XMLSchema#string

Yosra Aljawai

http://www.w3.org/2001/XMLSchema#string

Yuji Mishima

http://www.w3.org/2001/XMLSchema#string

P2860

HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing

Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche

HIF-1: upstream and downstream of cancer metabolism

PID: the Pathway Interaction Database

Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers

Lysyl oxidase is essential for hypoxia-induced metastasis

Glycolysis inhibition for anticancer treatment

Why do cancers have high aerobic glycolysis?

Targeting hypoxia in cancer therapy

THE METABOLISM OF TUMORS IN THE BODY

P304

2071-2082

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-14-3400

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

75

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-03-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25769724

http://www.w3.org/2001/XMLSchema#string

P921

multiple drug resistance

P932

4433568

http://www.w3.org/2001/XMLSchema#string